NeoGenomics results, outlook, call

 Fourth Quarter Revenue Increased 10% to $139 million;

Full Year Revenue Increased 5% to $510 million

2023 Financial Guidance

The Company also issued 2023 guidance(3) today (in millions).

	FY 2022		FY 2023 Guidance				YOY % Change from FY 2022
	Actual		Low		High		Low		High
Consolidated revenue	$510		$545		$555		7%		9%
Net loss	$(144)		$(116)		$(107)		19%		26%
Adjusted EBITDA	$(48)		$(27)		$(22)		44%		54%

(1) Clinical testing excludes requisitions, tests, revenue and costs of revenue for Pharma Services.

(2) The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net Loss, and Adjusted Diluted EPS. Each of these measures is defined in the section of this report entitled "Use of Non-GAAP Financial Measures." See also the tables reconciling such measures to their closest GAAP equivalent.

(3) The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.

Conference Call

The Company has scheduled a webcast and conference call to discuss its fourth quarter and full year 2022 results on Thursday, February 23, 2023 at 8:30 AM EDT. Interested investors should dial (888) 506-0062 (domestic) and (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 647216. A replay of the conference call will be available until 8:30 AM EDT on March 9, 2023, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID number is 47529. The webcast may be accessed under the Investor Relations section of our website at www.neogenomics.com. An archive of the webcast will be available until 8:30 AM EDT on February 23, 2024.

https://finance.yahoo.com/news/neogenomics-reports-fourth-quarter-full-120000351.html